Partner David Rosen was quoted in an Inside Health Policy article on January 22, 2014 titled “Generic Drug Industry Prioritizes Challenge to New Labeling Rule in 2014.” The article discusses the top priority for the generic drug industry in 2014 which will be combating a new regulation aimed at requiring generic drugmakers to make labeling changes to reflect new safety information. Rosen was quoted saying, “I think it’s going to be a pretty big deal.”
People
Related News
July 28, 2025
In the News
Mark Wolfson Honored in Florida Bar Spotlight
Foley & Lardner LLP partner Mark Wolfson was featured by The Florida Bar for his contributions to the Florida legal community in a "Past Chair Spotlight."
July 24, 2025
In the News
Margaret Nelson Assesses SEC Enforcement Philosophy
Foley & Lardner LLP partner Margaret Gembala Nelson commented in the Private Equity Law Report article, "SEC Enforcement Action Raises Potential Materiality Threshold for Conflicts of Interest," sharing insight on enforcement philosophy at the U.S. Securities and Exchange Commission.
July 24, 2025
In the News
Foley's Trial Team Featured Following Landmark Victory in Texas Trade Secret Case
Foley & Lardner LLP’s recent landmark appellate victory in a Texas trade secrets case is featured in the Texas Lawyer article, "Ruling Sets Precedent for Employment, Trade Secrets, Fiduciary Duty."